ENDOCRINOLOGY UPDATE  |  SUPPLEMENT SAFETY & LABORATORY INTERFERENCE

June 2026  |  NP Chronicles Clinical Education

 

Top Supplement and Vitamin Offenders in Endocrine Practice: When 'Natural' Becomes a Clinical Problem

By Valerie Watters-Burke, DNSc, MSN, MBA, FNP-BC, GNP-BC, PPCNP-BC

From the endocrine practice — evidence-based commentary on supplements that cause real patient harm and laboratory confusion

 

CLINICAL BOTTOM LINE

Nearly 60% of U.S. adults now use dietary supplements regularly — and the proportion approaches 80% in adults over 65. For NPs working in endocrinology, primary care, or any complex patient setting, vitamins and supplements are no longer background noise. They are active pharmacological variables that can falsify laboratory results, cause direct organ toxicity, interact with medications, and trigger unnecessary workups and procedures. This post covers the top offenders seen in endocrine practice — cases that resulted in false thyroid diagnoses, avoidable Cushing's evaluations, unnecessary surgery, liver transplant workup, and AKI. Know these. Ask about these. Every time.

 

The Clinical Problem: Supplements Are Hiding in Plain Sight

The supplement aisle has fundamentally changed the clinical complexity of laboratory interpretation and differential diagnosis. What used to be an occasional asterisk in a patient's medication history is now a routine pharmacologic exposure for the majority of your patients — and most of them do not think to mention it. Why would they? Supplements are not medications. They bought them at the drugstore. They are 'natural.' They are what their wellness influencer recommended.

But in endocrine practice — and increasingly in every specialty — supplements are causing real problems: laboratory values that suggest disease where none exists, laboratory values that obscure disease that is present, and direct organ toxicity that arrives weeks or months after the offending supplement was started. By the time the patient reaches a specialist, the downstream workup has already begun, and sometimes completed, incorrectly.

The clinical imperative: Think drugs, then supplements, then everything else. Before you order the next test or refer to a specialist, ask one more time — comprehensively — what the patient is putting in their body.

Top Offenders at a Glance: Master Reference Table

The table below covers the supplements most commonly encountered in endocrine practice that cause laboratory interference or direct clinical harm. Detailed discussion of each follows.

 

Supplement / Vitamin	Dose of Concern	Lab / Clinical Effect	Mechanism	NP Action
Biotin (Vitamin B7)	≥5–10 mg/day	False ↓ TSH; false ↑ free T4, free T3; false ↑ troponin or false ↓ troponin (assay-dependent); false ↑ PTH, estradiol, testosterone, LH, FSH	Biotin-streptavidin competitive interference in immunoassays	Hold biotin ≥2 days (ideally 5–7 days) before thyroid or cardiac lab draw. Ask about dose — most hair/nail products are 5–10 mg, not 30 mcg RDA.
Vitamin D (cholecalciferol / ergocalciferol)	Chronic high-dose: >4,000 IU/day in most adults; toxicity reported at >10,000 IU/day sustained	Hypercalcemia; hypercalciuria; nephrolithiasis; nephrocalcinosis; AKI; metastatic calcification; suppressed PTH	25-OH vitamin D is not tightly regulated; accumulates in fat. Excess 25-OH D drives calcium absorption through intestinal VDR and calcium reabsorption in kidney.	Check 25-OH vitamin D and calcium together. Do not target 25-OH D >60 ng/mL. For toxicity, withhold vitamin D; consider low-dose glucocorticoid to inhibit 1-alpha hydroxylase. Resolution takes 2–3 months.
Vitamin A (retinol / retinyl palmitate)	Acute toxicity: single dose >150,000 IU; Chronic toxicity: >25,000 IU/day for weeks-months	Hepatotoxicity (elevated transaminases, hepatic fibrosis); pseudotumor cerebri (ICP elevation); hypercalcemia; bone pain; teratogenicity	Retinol accumulates in hepatic stellate cells; activates HSCs leading to fibrosis. Retinol competes with vitamin K–dependent proteins affecting bone turnover.	Check serum retinol if suspicious. Stop supplement immediately — half-life is weeks. Liver biopsy may be needed for hepatotoxicity evaluation. Teratogenic: counsel women of childbearing age.
Vitamin E (alpha-tocopherol)	>400 IU/day for extended periods	Anticoagulant potentiation (elevated INR on warfarin); increased all-cause mortality in meta-analysis at high doses; may increase hemorrhagic stroke risk	Inhibits vitamin K–dependent coagulation factors (II, VII, IX, X); antagonizes platelet aggregation. Possible pro-oxidant effect at high concentrations.	Counsel patients on warfarin to avoid doses >100–200 IU/day. Screen for bleeding history. The SELECT trial showed vitamin E supplements did not reduce prostate cancer and may increase risk.
Glucosamine ± Chondroitin	Standard doses (1,500 mg glucosamine / 1,200 mg chondroitin)	Warfarin potentiation (elevated INR); possible hepatotoxicity (rare); new evidence links glucosamine to accelerated Alzheimer's disease progression in established AD/ADRD	Glucosamine may inhibit warfarin metabolism; feeds hexosamine biosynthetic pathway in the brain, driving N-glycan overproduction in neurodegeneration	Flag in all anticoagulated patients. Counsel discontinuation in patients with MCI or established dementia. Do not combine with warfarin without frequent INR monitoring.
5-Hydroxytryptophan (5-HTP)	Doses >100–200 mg/day; risk increases with concurrent serotonergic drugs	Diarrhea, nausea, GI dysmotility — can elevate urinary 5-HIAA on carcinoid screening; serotonin syndrome risk when combined with SSRIs, MAOIs, tramadol, triptans	5-HTP is the direct precursor to serotonin. Elevated peripheral serotonin metabolites cause false-positive 24-hour urine 5-HIAA (carcinoid/NEF tumor marker).	Stop 5-HTP ≥3 days before 24-hour urine 5-HIAA collection. Warn against concurrent use with serotonergic agents. Screen supplement list before carcinoid workup.
Exogenous steroids (hidden in 'adrenal support,' 'stress formulas,' injections from holistic providers)	Any dose of exogenous dexamethasone, prednisolone, or compounded steroid	Cushingoid features (moon face, weight gain, striae, HTN, hyperglycemia) WITH suppressed or undetectable serum/urine cortisol and suppressed ACTH; adrenal insufficiency on withdrawal	Exogenous synthetic corticosteroids suppress HPA axis. Many crossreact poorly with cortisol immunoassays — dexamethasone gives near-zero cortisol on standard assay, creating diagnostic confusion.	When Cushing's features + undetectable cortisol: suspect exogenous steroid, not endogenous Cushing's. Get full medication AND supplement list including injections. Taper slowly; adrenal recovery may take months.
Zinc (high-dose)	>40 mg/day chronically (UL = 40 mg/day for adults)	Copper deficiency (anemia, neutropenia, neurological symptoms: myeloneuropathy, gait disturbance); falsely low serum copper; secondary low ceruloplasmin	Zinc competitively inhibits intestinal copper absorption via metallothionein induction. High zinc upregulates MT, which binds copper preferentially in enterocytes, blocking systemic absorption.	Check serum copper and ceruloplasmin in patients taking high-dose zinc with unexplained anemia or neurological symptoms. Treat with copper replacement and zinc dose reduction.

 

Biotin (Vitamin B7): The Assay Saboteur

The Clinical Problem

Biotin is found in virtually every hair, skin, and nail supplement on the market — and increasingly in standalone capsules marketed for hair regrowth, nail strengthening, and metabolic support. The RDA for biotin is approximately 30 micrograms per day. Most therapeutic supplement products deliver 5,000 to 10,000 micrograms (5 to 10 milligrams) — 150 to 300 times the daily requirement.

At those doses, biotin causes clinically significant interference in immunoassays that use the biotin-streptavidin capture system. This platform is among the most widely used in clinical laboratory medicine — and it underlies many of the hormone assays your patients receive routinely.

The Mechanism

In biotin-streptavidin immunoassays, streptavidin-coated beads capture biotinylated antibodies that bind the analyte of interest. When excess biotin is present in the patient's serum, it competes with the biotinylated antibodies for streptavidin binding sites, reducing capture efficiency. Depending on the assay design:

•       In competitive assays (typically used for small molecules like T3, T4, estradiol), excess biotin causes false INCREASES in the reported analyte.

•       In sandwich immunoassays (typically used for larger molecules like TSH, troponin, PTH), excess biotin causes false DECREASES.

 

The net result in thyroid testing: false low TSH + false high free T4 = a laboratory picture indistinguishable from hyperthyroidism. In a patient with symptoms of anxiety, palpitations, or weight loss — none of which are specific — this can lead to unnecessary radioiodine uptake scanning, antithyroid drug initiation, or endocrinology referral.

Biotin Interference in Thyroid and Other Assays

 

Lab Test	Direction of Interference	Clinical Misinterpretation Risk
TSH	False DECREASE	Apparent hyperthyroidism or undetectable TSH → may trigger unnecessary workup or treatment
Free T4, Free T3	False INCREASE	Apparent overt hyperthyroidism when patient is euthyroid
Troponin	False DECREASE or false INCREASE (assay-dependent)	False negative: missed MI. False positive: unnecessary catheterization, treatment
PTH (parathyroid hormone)	False DECREASE	May obscure true hyperparathyroidism or misrepresent calcium-PTH relationship
Estradiol, Testosterone, LH, FSH	False INCREASE or DECREASE (assay-dependent)	Reproductive hormone misinterpretation; incorrect diagnosis of hypogonadism or PCOS
Vitamin B12, Folate, Ferritin	Variable by platform and assay design	Under- or over-treatment of nutritional deficiencies
24-hour urine 5-HIAA (carcinoid screen)	N/A — interference from 5-HTP not biotin; 5-HTP → elevated 5-HIAA	False-positive carcinoid screen. See 5-HTP section — holds same clinical lesson: always screen supplements before running tumor markers.

 

CASE FROM PRACTICE: Patients presenting with laboratory findings of apparent hyperthyroidism — suppressed TSH, elevated free T4 — without symptoms proportionate to those values should prompt the question: 'What supplements are you taking for your hair or nails?' Biotin interference is identified by holding the supplement for 5–7 days and repeating the labs. Normal repeat values confirm interference, not disease.

 

What to Do

•       Ask specifically about biotin-containing supplements at every thyroid-related visit. Most patients do not know their hair supplement contains high-dose biotin.

•       Hold biotin for a minimum of 2 days (5–7 days is preferable for doses ≥10 mg) before drawing thyroid function tests, troponin, or reproductive hormones.

•       If a patient presents with unexplained thyroid panel abnormalities — especially the TSH-low/fT4-high pattern — suspect biotin before initiating workup. Repeat off supplement.

•       The FDA issued a safety communication in 2017 and again in 2019 warning that biotin interference had caused clinically significant laboratory errors including a missed troponin in a patient with an acute MI. This is not theoretical.

 

Vitamin D: The Most Overused and Most Dangerous 'Safe' Supplement

Why Vitamin D Toxicity Is Underrecognized

Vitamin D is widely perceived as one of the safest supplements available — and at physiologic doses (600–2,000 IU/day for most adults), it largely is. But the marketing of vitamin D has outpaced the evidence by a significant margin. Patients have been told by influencers, integrative practitioners, and well-meaning lay publications that vitamin D prevents cancer, reverses autoimmune disease, prevents COVID, and extends life. The actual evidence is far more modest.

What has not kept pace with the marketing: public understanding that vitamin D is fat-soluble, stores in adipose tissue for months, is not tightly regulated by the body at high doses, and can cause serious toxicity when overused. Unlike water-soluble vitamins that are excreted renally when in excess, fat-soluble vitamin D accumulates.

The Toxicity Mechanism

Vitamin D toxicity occurs through hypervitaminosis D — excessive 25-hydroxyvitamin D (25-OH D) driving supraphysiologic activation of intestinal vitamin D receptors (VDR), dramatically increasing calcium absorption. Simultaneously, high 25-OH D increases renal calcium reabsorption and bone resorption. The result is hypercalcemia, which if sustained causes:

•       Nephrolithiasis (calcium oxalate and calcium phosphate stones)

•       Nephrocalcinosis — calcification of renal parenchyma

•       Acute kidney injury from calcium-mediated renal vasoconstriction and direct tubular toxicity

•       Metastatic soft tissue calcification (blood vessels, cardiac valves, cornea)

•       Suppressed PTH (appropriate physiologic response, but complicates differential diagnosis)

•       Neuropsychiatric symptoms: cognitive changes, depression, weakness

 

CASE FROM PRACTICE: A patient presented with hypercalcemia, nephrolithiasis, and markedly suppressed PTH. The 25-OH vitamin D level was >500 ng/mL. Investigation revealed she had been taking 100,000 IU of vitamin D daily — not 1,000 IU — for 18 months, having misread a supplement recommendation. This case was published as a case report. Vitamin D toxicity at this level is survivable but requires aggressive management and months of monitoring.

 

Safe vs. Toxic Dose Thresholds

•       RDA: 600 IU/day for adults 19–70; 800 IU/day for adults >70

•       Tolerable Upper Intake Level (UL): 4,000 IU/day for adults (National Academies of Sciences, Engineering, and Medicine)

•       Routine supplementation without monitoring: generally ≤2,000 IU/day is safe for most adults

•       Toxicity reported: typically with sustained intake >10,000 IU/day; individual susceptibility varies

•       Target 25-OH D levels: 20–40 ng/mL is sufficient for bone health per most guidelines; targeting 80–100 ng/mL substantially increases calciuria and stone risk without proven added benefit

 

NOTE: Granulomatous diseases (sarcoidosis, TB, fungal infections) and some lymphomas produce ectopic 1-alpha hydroxylase, converting 25-OH D to active 1,25(OH)2 D independently of PTH. These patients are exquisitely sensitive to even normal-dose vitamin D supplementation and can develop hypercalcemia with standard doses. Always check for granulomatous disease in hypercalcemia with suppressed PTH before attributing the picture to supplement excess alone.

 

Management of Vitamin D Toxicity

 

Scenario / Step	Details
Confirm toxicity	25-OH vitamin D >150 ng/mL with symptomatic hypercalcemia, hypercalciuria, or AKI is consistent with toxicity. Check: 25-OH D, 1,25(OH)2 D, serum calcium, albumin, phosphorus, PTH, BMP/CMP, 24-hour urine calcium.
Stop vitamin D immediately	Discontinue all vitamin D-containing supplements. Check all multivitamins, calcium + D combos, and fortified foods if intake is extreme. Eliminate sun exposure contribution if severe.
Hydration	IV normal saline for symptomatic hypercalcemia. Forced saline diuresis increases urinary calcium excretion. Loop diuretics (furosemide) may be added after volume repletion to enhance calciuresis — never before adequate hydration.
Glucocorticoid therapy (bridge)	Prednisone 20–40 mg/day (or equivalent hydrocortisone) inhibits intestinal 1-alpha hydroxylase activity, reducing conversion of 25-OH D to active 1,25(OH)2 D. Effect seen within days; reduces calcium absorption and corrects hypercalcemia faster than simply stopping the supplement. Use as bridge while vitamin D stores clear.
Expected timeline for resolution	25-OH vitamin D stored in adipose tissue clears slowly. At very high initial levels, expect 2–3 months for normalization even after complete cessation. Serial 25-OH D and calcium monitoring monthly until normalized.
Patient education	Review all supplements at discharge. Most patients do not understand that 'natural' supplements carry overdose risk. Provide written materials specifying the safe upper limit (4,000 IU/day for most adults; 2,000 IU/day for most routine supplementation without monitoring).

 

Vitamin A: Liver Toxicity, Pseudotumor Cerebri, and Teratogenicity

The Underappreciated Danger of Retinol

Vitamin A (retinol) is the fat-soluble vitamin most likely to cause serious toxicity at doses that patients consider 'high dose wellness.' Unlike vitamin D, which has received extensive public attention for both its benefits and its toxicity, vitamin A toxicity remains underrecognized — partly because it is marketed primarily through cosmetic and anti-aging lenses, and partly because its symptoms (fatigue, headache, dry skin, nausea) are nonspecific in early stages.

Vitamin A stored in hepatic stellate cells (HSCs) can directly activate them, promoting hepatic fibrosis. At sufficiently high doses over a long period, this can progress from subclinical hepatotoxicity to cirrhosis. Liver transplantation for vitamin A toxicity has been documented in the literature — representing an entirely preventable iatrogenic catastrophe.

Clinical Manifestations by Dose

•       Acute toxicity (single dose >150,000 IU): headache, nausea, vomiting, blurred vision, fontanelle bulging in infants, increased intracranial pressure

•       Chronic toxicity (>25,000 IU/day for weeks to months): hepatomegaly, elevated transaminases, hepatic fibrosis, hypercalcemia, periosteal bone changes, dry/cracked skin, hair loss

•       Pseudotumor cerebri: idiopathic intracranial hypertension with headache, papilledema, visual changes — documented with chronic high-dose vitamin A

•       Teratogenicity: vitamin A in doses >10,000 IU/day in early pregnancy causes craniofacial, cardiac, thymic, and CNS malformations. Isotretinoin (a synthetic retinoid) carries a Category X classification for this reason.

 

CASE FROM PRACTICE: A woman presented with significantly elevated liver enzymes, progressive fatigue, and right upper quadrant discomfort. She had been taking high-dose vitamin A for several months based on advice that retinol would reduce facial wrinkles. Her supplement dose was approximately 50,000 IU/day — roughly 10x the safe upper limit. Liver biopsy showed hepatic fibrosis. She required hepatology consultation and was evaluated for liver transplantation. The supplement was the sole etiology.

 

Diagnosis and Management

•       Serum retinol level: normal range is approximately 20–60 mcg/dL; toxicity typically presents with levels >100 mcg/dL

•       Stop the supplement immediately — half-life of stored retinol is weeks; clinical improvement is gradual

•       LFTs, RUQ ultrasound, and hepatology referral for significant hepatotoxicity

•       Counsel women of childbearing age explicitly: avoid vitamin A supplements >5,000 IU/day, and particularly avoid during the periconception period and first trimester

•       Beta-carotene (provitamin A from plant sources) is NOT associated with the same toxicity — the body regulates conversion of beta-carotene to retinol. The danger is from preformed retinol (retinyl palmitate, retinyl acetate) in animal-source or synthetic supplements.

 

Vitamin E: The Anticoagulant You Didn't Prescribe

Clinical Relevance in Practice

Vitamin E (alpha-tocopherol) is broadly perceived as a harmless antioxidant. It has been studied extensively for cardiovascular disease prevention, prostate cancer prevention, and cognitive protection — and in nearly every high-quality trial, supplemental vitamin E at doses above dietary intake has failed to demonstrate benefit and has, in several cases, caused harm.

The most immediately actionable issue for NPs: vitamin E at doses above 400 IU/day inhibits vitamin K–dependent coagulation factors (II, VII, IX, X) and interferes with platelet aggregation. In patients on warfarin, concurrent vitamin E supplementation can significantly elevate INR and increase bleeding risk. Many patients on warfarin take vitamin E as part of an antioxidant supplement without any awareness of this interaction — and may not disclose it because it is 'just a vitamin.'

The Evidence Against High-Dose Vitamin E

•       SELECT trial (Selenium and Vitamin E Cancer Prevention Trial, JAMA 2011): vitamin E 400 IU/day significantly increased the risk of prostate cancer among healthy men — a finding that was the opposite of the supplement's marketing claim.

•       Meta-analysis (Miller et al., Annals of Internal Medicine 2005): high-dose vitamin E supplementation (≥400 IU/day) associated with increased all-cause mortality.

•       HOPE trial: vitamin E provided no cardiovascular benefit in high-risk patients; subsequent HOPE-TOO showed increased risk of heart failure with long-term use.

 

Dietary vitamin E from food sources (nuts, seeds, leafy greens) is not associated with these risks. The harm is specific to high-dose supplemental alpha-tocopherol — reinforcing that dose, form, and source matter even for vitamins considered uniformly safe.

5-Hydroxytryptophan (5-HTP): The False Carcinoid

How a Supplement Triggers a Cancer Workup

5-Hydroxytryptophan is the direct metabolic precursor to serotonin (5-hydroxytryptamine). It is marketed for mood support, anxiety reduction, sleep, and appetite regulation — and it is widely available without a prescription. At doses above 100–200 mg/day, it floods the peripheral serotonin synthesis pathway, dramatically increasing serotonin production in enterochromaffin cells throughout the GI tract.

The clinical consequence: 5-HTP causes diarrhea, GI cramping, and other GI dysmotility symptoms that are clinically indistinguishable from the symptoms of a carcinoid tumor (neuroendocrine tumor, NET). When a provider orders a 24-hour urine 5-hydroxyindoleacetic acid (5-HIAA) to screen for carcinoid in a patient with diarrhea, 5-HTP supplementation will cause a markedly elevated result — a biochemical false positive for NET.

CASE FROM PRACTICE: A patient presented with persistent diarrhea and flushing. She was taking 5-HTP for mood support. A 24-hour urine 5-HIAA was drawn without screening for supplements. The result was markedly elevated. Imaging and subsequent surgical exploration for a presumed carcinoid tumor were performed. No tumor was found. A comprehensive supplement review after the procedure identified the 5-HTP. The surgery was entirely preventable.

 

The Serotonin Syndrome Risk

Beyond the false-positive carcinoid screen, 5-HTP carries a genuine safety risk when combined with serotonergic medications:

•       SSRIs (sertraline, fluoxetine, escitalopram, etc.)

•       SNRIs (venlafaxine, duloxetine)

•       Tramadol (weak serotonin reuptake inhibitor)

•       MAOIs (rare but clinically important)

•       Triptans (serotonin 1B/1D agonists)

•       Linezolid (weak MAO inhibitor)

 

The combination can produce serotonin syndrome — ranging from mild (tremor, diarrhea, hyperreflexia) to severe (hyperthermia, rhabdomyolysis, seizures, cardiovascular instability). Screening for 5-HTP use in any patient on serotonergic medications is a patient safety imperative.

Hidden Exogenous Steroids: Cushing's That Isn't

The Pattern You Need to Recognize

Some of the most diagnostically confusing patients in endocrine practice present with unambiguous Cushingoid features — moon facies, central adiposity, proximal muscle weakness, easy bruising, purple striae, hypertension, hyperglycemia — alongside laboratory results showing suppressed or completely undetectable serum cortisol and low ACTH. This combination is not consistent with endogenous Cushing's syndrome. It is the hallmark of exogenous steroid exposure.

The sources are more varied than most providers expect:

•       'Adrenal support' or 'adrenal fatigue' supplements that contain undisclosed low-dose prednisone, prednisolone, or dexamethasone — often compounded or sourced outside conventional pharmacy

•       Herbal formulations from international pharmacies or holistic providers that contain corticosteroid adulterants

•       Intramuscular or intravenous injections administered by integrative, naturopathic, or wellness providers — often marketed as 'vitamin shots,' 'immune boosters,' or 'anti-inflammatory injections'

•       Topical steroid preparations (skin creams, nasal sprays, inhaled steroids) in excessive doses or via occlusive application

•       Compounded 'hormone balancing' preparations that include corticosteroids

 

The Diagnostic Trap

Standard immunoassays for serum cortisol measure endogenous cortisol (hydrocortisone). Synthetic corticosteroids — particularly dexamethasone and prednisolone — cross-react poorly or not at all with these assays. A patient taking exogenous dexamethasone will have profoundly suppressed HPA axis function AND an apparent serum cortisol of nearly zero — mimicking primary adrenal insufficiency in combination with the Cushingoid features. Without knowing about the steroid exposure, this presentation is deeply confusing.

⚠ Diagnostic key: Cushingoid features + undetectable cortisol = suspect exogenous steroid first. True endogenous Cushing's presents with ELEVATED cortisol. A Cushingoid-appearing patient with low or undetectable cortisol should never be evaluated for endogenous Cushing's before exogenous steroid exposure has been excluded.

 

Management Considerations

•       Get the complete supplement and injection history — ask specifically about injections received outside a conventional medical office or pharmacy

•       Urine steroid metabolomics or mass spectrometry (not standard immunoassay) can identify specific exogenous steroids in the urine when the source is unclear

•       Do not abruptly stop exogenous steroids — HPA axis suppression may be profound; patients need a structured taper

•       HPA axis recovery can take 6–12 months after prolonged exogenous steroid exposure; serial morning cortisol or stimulation testing is required to document recovery

 

The Fat-Soluble Vitamins: A Framework for Risk

Vitamins A, D, E, and K are all fat-soluble — meaning they are absorbed in the GI tract with dietary fat, packaged into chylomicrons, and stored in adipose tissue and the liver. Unlike water-soluble vitamins (B vitamins, vitamin C), they are not readily excreted in urine when taken in excess. This creates an accumulation dynamic that is both the source of their therapeutic value at physiologic doses and the basis of their toxicity at supraphysiologic doses.

The critical clinical principle:

Fat-soluble vitamins are easy to measure, but treating toxicity takes a long time. Accumulation occurs over weeks to months; clearance occurs over weeks to months. A patient who has been taking excessive vitamin D for six months will not resolve their hypervitaminosis in two weeks of stopping. Plan for serial monitoring and patient education about the long timeline of resolution.

The clinical question is never just 'what is the level today?' — it is 'how long have they been taking it, and at what dose?' Both variables determine how serious the accumulation is and how long management will take.

 

A Framework for Supplement-Driven Diagnostic Errors: Think Before You Test

The pattern across these cases is consistent: a laboratory abnormality or clinical syndrome that suggests a specific diagnosis leads to workup, which may include imaging, additional lab testing, procedures, or specialist referral — all driven by a supplement that was never elicited in the history. The errors are downstream of a missed question, not downstream of provider incompetence.

Build these reflexes into your clinical reasoning:

1.    False thyroid panel → Ask about biotin before you order a nuclear medicine scan or start antithyroid drugs.

2.    Cushingoid features + low cortisol → Ask about injections and supplement products before you order 24-hour urine free cortisol or pituitary imaging.

3.    Diarrhea + flushing → Ask about 5-HTP before you order a 24-hour urine 5-HIAA.

4.    Hypercalcemia + suppressed PTH → Check 25-OH vitamin D, 1,25(OH)2 D, and a granulomatous disease screen before concluding the cause.

5.    Elevated liver enzymes without obvious etiology → Ask specifically about vitamin A, herbal supplements, and injectable products.

6.    Unexplained anemia + neurological symptoms → Check serum copper and zinc; ask about high-dose zinc supplementation.

7.    Elevated INR without medication change in a warfarin patient → Ask about vitamin E, fish oil, garlic, turmeric, and other supplement additions.

 

Creating a Supplement-Inclusive Practice Environment

Patients do not disclose supplements for several reasons: they do not think supplements count as medications, they expect judgment from providers, they believe natural products are categorically safe, or they simply were not asked. The solution is structural, not individual.

•       Ask with specificity. 'Do you take any supplements, vitamins, herbal products, injections from wellness providers, or products for hair, skin, weight loss, or energy?' is more productive than 'any medications?'

•       Ask without judgment. Patients who sense that you consider supplements naive or dangerous will stop disclosing. Frame the question as clinical information-gathering: 'Everything you take is something I want to know about so I can interpret your labs correctly.'

•       Have patients bring the bottles. A phone photo of the supplement label is adequate if they cannot bring the physical products. The label reveals dose, form, and additional ingredients that patient recall often omits.

•       Document everything in the chart. Supplements should be listed in the medication section alongside prescription drugs — not buried in a social history note that may not be reviewed.

•       Revisit at every visit. Supplement use changes frequently. The patient who was not taking anything at their last appointment may have started six new products in response to an online wellness trend since you last saw them.

 

For NP Students and Board Exam Prep

Vitamin toxicity and supplement-related laboratory interference are high-yield board topics. Key testable concepts include:

8.    Fat-soluble vitamins: Know which vitamins are fat-soluble (A, D, E, K) and why they accumulate rather than being excreted. Know the clinical presentations of A and D toxicity specifically.

9.    Biotin interference: The mechanism (biotin-streptavidin competitive interference) and the clinical consequence (false thyroid panel) are board-testable. Know that holding biotin 2–7 days before testing resolves the interference.

10. Hypercalcemia differential: The combination of hypercalcemia + suppressed PTH should generate a differential that includes vitamin D toxicity, granulomatous disease (sarcoidosis, TB), and malignancy. Board questions test whether you can navigate this differential correctly.

11. Vitamin E and warfarin: Fat-soluble vitamins affecting coagulation are testable. Vitamin E inhibits vitamin K–dependent factors — this is distinct from vitamin K supplementation, which reverses warfarin.

12. Serotonin syndrome: Know the triad (mental status changes, autonomic instability, neuromuscular abnormalities) and the drug and supplement combinations that trigger it. 5-HTP plus an SSRI is a board-worthy example.

 

The Bottom Line

The supplement landscape has permanently changed the complexity of clinical medicine. In endocrine practice — where laboratory values drive diagnosis and treatment — this is not an abstract concern. Supplements are causing false diagnoses, unnecessary procedures, avoidable organ toxicity, and in extreme cases, irreversible harm.

Your most powerful clinical tool is the question you ask before you order the next test. Think drugs, then supplements, then everything else. Ask specifically. Document completely. And apply the same evidence-based scrutiny to what patients put in their mouths voluntarily that you apply to what you prescribe.

The fat-soluble vitamins are not inherently dangerous. High-dose fat-soluble vitamin supplementation without monitoring, for extended periods, without clinical rationale, is.

 

 

Selected References

•       FDA Safety Communication: The FDA warns that biotin may interfere with lab tests. 2019. fda.gov

•       Araki T et al. Medical food-induced high-dose biotin interference with thyroid tests. Thyroid. 2015;25(9):945–6.

•       Holick MF et al. Evaluation, treatment, and prevention of vitamin D deficiency. J Clin Endocrinol Metab. 2011;96(7):1911–30.

•       National Academies of Sciences. Dietary Reference Intakes for Calcium and Vitamin D. 2011. National Academies Press.

•       Penniston KL, Tanumihardjo SA. The acute and chronic toxic effects of vitamin A. Am J Clin Nutr. 2006;83(2):191–201.

•       Miller ER et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37–46.

•       Klein EA et al. (SELECT trial). Vitamin E and the risk of prostate cancer. JAMA. 2011;306(14):1549–56.

•       Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther. 2006;109(3):325–38.

•       Hawkinson TR, Liu Z, et al. Hyperglycosylation is a metabolic driver of Alzheimer's disease. Nature Metabolism. 2026. doi:10.1038/s42255-026-01538-4 [glucosamine-AD link]

•       Lam CS et al. Emerging Patterns in Dietary Supplement Use Among US Adults, 1999–2023. JAMA Netw Open. 2026;9(6):e2619291.

 

© 2026 NP Chronicles | Clinical Education for NP Students and New Graduates | npchronicles.com

This post is intended for educational purposes. All clinical cases are presented for educational illustration. Always apply individualized clinical judgment and consult current guidelines for patient care decisions.

 

NFECTIOUS DISEASE  |  STI PREVENTION & SEXUAL HEALTH

June 2026  |  NP Chronicles Clinical Education

 

DoxyPEP in 2026: What Every NP Needs to Know About Prescribing, Patient Selection, and Antibiotic Stewardship

By Valerie Watters-Burke, DNSc, MSN, MBA, FNP-BC, GNP-BC, PPCNP-BC

Based on: Bacic Lima D. DoxyPEP in 2026: Who Benefits, How to Prescribe, and What to Watch. Infectious Disease Special Edition. April 23, 2026. idse.net

 

CLINICAL BOTTOM LINE

DoxyPEP — doxycycline 200 mg taken within 72 hours after unprotected sexual exposure — is now CDC-endorsed, evidence-backed, and increasingly part of routine STI prevention practice for MSM and transgender women who have sex with men. NPs in primary care, sexual health, family practice, telehealth, and urgent care settings are encountering patients who have already heard of it and want to discuss it. This post gives you everything you need: the trial data, candidacy criteria, prescribing details, counseling points, and the resistance conversation — organized for clinical use.

 

Why NPs Need to Know DoxyPEP Now

Your patients are ahead of you on this one. Doxycycline post-exposure prophylaxis has been covered extensively in lay media, LGBTQ+ health forums, and online HIV prevention communities. Patients on HIV PrEP — a population that many NPs now manage routinely — are asking about doxyPEP at the same visit. Non-ID providers are encountering it in telehealth queues, urgent care settings, and college health centers.

The good news: this is a genuinely practical, affordable, learnable intervention. Unlike many pharmacologic advances, doxyPEP does not require a new workflow, specialized equipment, or subspecialty referral. It can be integrated into an existing PrEP or sexual health visit in minutes. The prescription is straightforward. The evidence for appropriate populations is solid. And the monitoring cadence you already use for PrEP applies here.

What doxyPEP is: A patient-managed, event-driven strategy — doxycycline 200 mg taken once within 72 hours after unprotected sexual exposure — to reduce the risk of bacterial STIs, primarily syphilis and chlamydia.

What doxyPEP is not: A treatment for active STIs, a substitute for HIV PrEP, a replacement for condoms or vaccination, or a strategy for all populations or all STIs.

The Evidence: What the Randomized Trials Show

DoxyPEP has been evaluated in four landmark trials. Understanding what each showed — and for whom — is essential for appropriate prescribing and patient counseling.

 

Trial	Population	Chlamydia / Syphilis	Gonorrhea
IPERGAY Sub-Study (France)	MSM on HIV PrEP N=212	~70% relative risk reduction	No significant reduction
US DoxyPEP Trial (SF & Seattle)	MSM & TGW on PrEP or HIV+ N=501	~2/3 reduction in combined incidence; ~55% reduction in gonorrhea	~55% reduction (best gonorrhea result)
dPEP Kenya Study	Cisgender women ages 18-30 on PrEP n=449	No significant reduction	No significant reduction
DOXYVAC Study (France)	MSM on PrEP ≥6 months with ≥1 bacterial STI in prior 12 months N=545	Strong reduction	Lower efficacy

 

Reading the Data: Key Clinical Takeaways

Syphilis and chlamydia: consistent and strong. Across every trial that enrolled MSM and transgender women, reductions in syphilis and chlamydia were robust — approximately 70% relative risk reduction in the IPERGAY sub-study, strong reductions confirmed in the US DoxyPEP trial and DOXYVAC. This is the core efficacy signal and should anchor your patient counseling.

Gonorrhea: variable and concerning. The gonorrhea picture is more complicated. The US DoxyPEP trial showed approximately 55% reduction in incident gonorrhea — the best result across any trial. But the French trials (IPERGAY, DOXYVAC) showed little to no gonorrhea benefit, likely reflecting higher baseline tetracycline resistance in France. In the United States, tetM-mediated tetracycline resistance in Neisseria gonorrhoeae has risen to at least 30% as of early 2025, and the trend is upward. Patients should understand that doxyPEP is not a reliable gonorrhea prevention strategy.

Cisgender women: no demonstrated efficacy. The dPEP Kenya trial showed no significant reduction in bacterial STI incidence in cisgender women ages 18–30 on HIV PrEP. Hair drug level analysis in a subset revealed suboptimal adherence despite high self-reported adherence. Additionally, unfavorable vaginal tissue pharmacokinetics — particularly for patients taking doxyPEP closer to the 72-hour limit — may reduce efficacy after vaginal exposure. DoxyPEP should not be routinely offered to cisgender women; individualized shared decision-making is required when requested.

NOTE on cisgender heterosexual men: There are no RCT data on doxyPEP efficacy in cisgender heterosexual men. This population was not included in the landmark trials. Prescribing in this setting is off-label without supporting evidence and requires individualized discussion.

 

Who to Offer DoxyPEP: A Candidacy Framework

The CDC recommends discussing and offering doxyPEP to MSM and TGW who have had at least one bacterial STI (syphilis, chlamydia, or gonorrhea) in the preceding 12 months. This mirrors the eligibility criteria of the landmark trials and identifies patients in high-incidence sexual networks where benefit is most clearly established.

Additional CDC guidance supports discussing doxyPEP with MSM and TGW who may not yet have had a documented STI but are at increased risk. The key factors are: the patient is motivated, understands the evidence and its limits, and is committed to follow-up STI screening.

 

Clinical Question	Guidance
Is the patient MSM or TGW who has sex with men?	YES → Strong evidence from RCTs. Offer doxyPEP. NO → Do not routinely offer. Individualize only after careful shared decision-making, data counseling, and commitment to follow-up.
Has there been a bacterial STI in the last 12 months, or is there ongoing high risk?	YES → Offer doxyPEP. Mirrors landmark trial eligibility. NO → Consider if patient strongly prefers and will adhere to follow-up. Reinforce vaccines, condoms, and screening. Reassess candidacy frequently.
Are there current symptoms of chlamydia, gonorrhea, or syphilis?	YES → Evaluate and treat the active STI first per guidelines. Consider starting doxyPEP after treatment completion. NO → Proceed to offer doxyPEP if other criteria are met.
Is the patient a cisgender woman or heterosexual cisgender man?	Evidence is insufficient. The Kenya dPEP trial showed no efficacy in cisgender women; adherence issues and unfavorable vaginal pharmacokinetics are implicated. Individualize with robust shared decision-making. Do not routinely prescribe.

 

How to Prescribe DoxyPEP: The Clinical Details

DoxyPEP can typically be initiated in the same visit where HIV prevention, HIV care, or STI testing is being addressed. The prescribing framework is straightforward and the follow-up cadence aligns with existing PrEP monitoring.

 

Item	Details
Dose	Doxycycline hyclate OR monohydrate 200 mg (two 100-mg tablets/capsules) as soon as possible after unprotected oral or anal sex — no later than 72 hours after exposure.
Maximum	200 mg per 24 hours regardless of number of sex acts in that window.
Quantity	Prescribe enough until next follow-up based on anticipated use. Common practice: 60 tablets (30 doses); reassess at 3 months.
Formulation	Hyclate and monohydrate are both acceptable. Monohydrate may have fewer GI side effects but availability/coverage varies.
Administration	Take with a full glass of water. Remain upright for at least 30 minutes after. Best tolerated with food. Separate from iron, calcium, magnesium, and other polyvalent cations by at least 2 hours.
Side Effects	Nausea, reflux, diarrhea, photosensitivity, pill esophagitis, fixed drug eruptions. Take with food to minimize GI effects.
Follow-Up	Reassess ongoing need every 3–6 months. Screen for STIs (syphilis serology + site-specific gonorrhea and chlamydia NAAT) at each visit. 3-month interval aligns with HIV PrEP follow-up.
What It Does NOT Prevent	HIV, HSV, mpox, hepatitis, or other viral STIs. Not a replacement for HIV PrEP/PEP, condoms, vaccination, or routine STI screening.

 

A Note on Formulation: Hyclate vs. Monohydrate

Both formulations are clinically acceptable. Doxycycline monohydrate is less acidic and less water-soluble than hyclate, and some data suggest it may have a lower incidence of GI side effects — particularly nausea and esophageal irritation. However, formulary availability and insurance coverage vary significantly. The clinical priority is ensuring the patient can actually obtain and afford the medication; efficacy between the two salt forms is equivalent.

Practical Counseling: What to Tell Your Patients

Keeping the counseling brief, clear, and consistent is the priority. A one-page written handout reinforces verbal instruction and reduces errors — particularly important when patients are also learning on-demand HIV PrEP (the 2-1-1 regimen), which has a different dosing schedule. Patients can easily confuse the two.

The Core Messages

•       Sooner is better. The studied window is up to 72 hours, but taking doxyPEP earlier — ideally within 24 hours — is likely more effective. Timing matters.

•       DoxyPEP works best for syphilis and chlamydia. It is not reliable for gonorrhea prevention, and it does not prevent HIV, HSV, mpox, or other viral STIs.

•       DoxyPEP is one tool in a toolkit, not a standalone strategy. It works best alongside HIV PrEP (if indicated), HPV and hepatitis B vaccination, regular STI screening, and condoms when desired.

•       Take it correctly. Full glass of water, stay upright for at least 30 minutes, with food if possible. Avoid taking it with dairy, antacids, iron, or calcium supplements at the same time.

•       Follow-up matters. STI testing every 3 months is part of the doxyPEP regimen — not optional. This is how infections are caught early and how your ongoing candidacy is reassessed.

•       It does not replace PrEP. If you are on HIV PrEP, continue it. DoxyPEP and HIV PrEP are different drugs for different purposes and are used together, not interchangeably.

 

Practical tip: When a patient is starting both on-demand HIV PrEP (2-1-1) and doxyPEP at the same visit, use a side-by-side written comparison. '2-1-1 for HIV prevention BEFORE and AFTER sex' vs. 'DoxyPEP 200 mg AFTER sex within 72 hours.' The timing and trigger are different enough that verbal-only counseling leads to errors.

 

The Antibiotic Resistance Conversation: What You Need to Know

Any time an antibiotic is used for prophylaxis rather than treatment, stewardship questions arise. For doxyPEP, three resistance concerns deserve clinical attention.

1. Gonorrhea: The Most Immediate Concern

Neisseria gonorrhoeae has significant baseline tetracycline resistance, mediated primarily by the tetM gene, which encodes a ribosomal protection protein that prevents doxycycline from binding effectively to the bacterial ribosome. This gene is carried on mobile genetic elements (plasmids and transposons) that can transfer between bacterial species.

tetM-carrying N. gonorrhoeae has been expanding in the United States — rising to at least 30% resistance as of early 2025 according to surveillance data published in NEJM. This is the primary reason gonorrhea efficacy in doxyPEP trials has been inconsistent and why the signal will likely weaken further as doxyPEP use scales nationally. Patients should be counseled explicitly: doxyPEP should not be relied upon for gonorrhea prevention.

2. Bystander Resistance: Staph aureus and the Microbiome

Early surveillance data suggest that heavier doxyPEP use may be associated with increased tetracycline-resistant Staphylococcus aureus colonization in the nasopharynx of exposed individuals. Because the resistance genes (tetM, others) are frequently located on mobile genetic elements, they can travel alongside other resistance determinants — including genes that increase minimum inhibitory concentrations for beta-lactams (such as penA).

The clinical significance of this bystander resistance in real-world populations is still being characterized. It is not a reason to withhold doxyPEP from appropriate candidates, but it is a reason to continue monitoring through surveillance programs and to avoid prescribing doxyPEP in populations where the benefit-risk calculation is unclear (cisgender women, low-risk patients, those unable to adhere to follow-up).

3. Chlamydia and Syphilis: No Resistance Signal (Yet)

The reassuring finding: there is no identified resistance signal that undermines doxyPEP's effectiveness against Chlamydia trachomatis or Treponema pallidum. These remain the strongest efficacy targets, and surveillance through 2025 has not identified meaningful doxycycline resistance in these organisms. Continued monitoring is warranted as use scales — but the current evidence does not raise a near-term chlamydia or syphilis resistance concern.

For NPs managing doxyPEP patients: Document every prescription with the indication (doxyPEP for bacterial STI PEP), the population (MSM/TGW with documented STI risk), and the follow-up plan. This supports stewardship tracking, enables population-level surveillance, and demonstrates appropriate prescribing practice.

 

Integrating DoxyPEP Into Your Practice Workflow

DoxyPEP does not require a new visit type or a separate workflow. The most practical approach is integration with existing HIV PrEP visits, sexual health appointments, or STI testing encounters. The follow-up cadence — every 3 months — is identical to HIV PrEP monitoring.

At the Initiating Visit

1.    Take a baseline sexual history and STI risk assessment. Document population (MSM/TGW with male partners), recent STI history, and current STI risk factors.

2.    Rule out active STI symptoms. If symptomatic, evaluate and treat first, then consider doxyPEP initiation after treatment.

3.    Order baseline STI screening: syphilis serology (RPR or VDRL), site-specific NAAT for gonorrhea and chlamydia (genital, rectal, pharyngeal as appropriate).

4.    Counsel using the core messages above. Provide written instructions.

5.    Prescribe: doxycycline hyclate or monohydrate 100 mg tablets, #60 tablets (30 doses), take 2 tablets within 72 hours of unprotected sex. Refills: 0 until follow-up.

6.    Schedule 3-month return for STI rescreening and reassessment of ongoing doxyPEP candidacy.

 

At Follow-Up Visits (Every 3 Months)

7.    Review doxyPEP use: how often used, any missed doses, any side effects.

8.    Repeat STI panel: syphilis serology, site-specific gonorrhea and chlamydia NAAT.

9.    Reassess ongoing candidacy: Has risk behavior changed? Are there new contraindications?

10. Refill prescription if still indicated. Adjust quantity based on actual reported use.

11. Reinforce counseling. Review written instructions again if dosing errors have occurred.

 

EMR tip: Build a doxyPEP order set that auto-generates the doxycycline prescription, STI screening labs, and a 3-month follow-up reminder in one click. This is the most impactful structural change you can make to increase uptake in a busy practice.

 

For NP Students and Board Exam Prep

DoxyPEP is recent enough that it may or may not appear on your board exam, but the underlying concepts certainly will. Here is how to connect this topic to testable frameworks:

12. STI epidemiology: Know the key bacterial STIs — syphilis (Treponema pallidum), gonorrhea (Neisseria gonorrhoeae), and chlamydia (Chlamydia trachomatis). Understand their transmission routes, screening recommendations, and first-line treatment regimens.

13. PrEP vs. PEP: Pre-exposure prophylaxis (taken before exposure to prevent infection) vs. post-exposure prophylaxis (taken after exposure). DoxyPEP is a post-exposure strategy. HIV PrEP is a pre-exposure strategy. Students commonly confuse these.

14. Tetracycline class pharmacology: Doxycycline is a second-generation tetracycline. Mechanism: binds the 30S ribosomal subunit, blocking aminoacyl-tRNA binding and inhibiting protein synthesis. Coverage: broad-spectrum, including intracellular organisms (Chlamydia, Rickettsia, Borrelia). Key contraindications: pregnancy, children under 8 years (permanent tooth staining and bone growth inhibition).

15. Antibiotic resistance mechanisms: For boards, know the major mechanisms — beta-lactamase production, ribosomal modification (relevant to tetracyclines via tetM), efflux pumps, and altered target sites. The ability of resistance genes to transfer via mobile genetic elements (plasmids) is a key stewardship concept.

16. Shared decision-making: DoxyPEP is a high-yield clinical communication example. Board questions may test your ability to identify appropriate candidates, recognize populations where evidence is insufficient, and demonstrate the elements of informed consent — including disclosure of evidence limitations.

 

The Bottom Line

Bacterial STIs — syphilis, chlamydia, and gonorrhea — are at historically high levels in the United States. For MSM and transgender women who have sex with men, doxyPEP is a proven, affordable, and practical addition to the prevention toolkit. It is CDC-endorsed, supported by multiple randomized trials, and consistent with real-world implementation data showing meaningful reductions in syphilis and chlamydia.

NPs are well-positioned to prescribe doxyPEP — particularly those already managing HIV PrEP, providing sexual health care, or working in telehealth settings where these conversations happen daily. The skill set required is already yours: sexual history taking, shared decision-making, STI screening interpretation, and routine follow-up.

What patients need from you is straightforward: accurate information about who benefits and who doesn't, clear prescribing instructions, honest counseling about what doxyPEP can and cannot do, and a commitment to the 3-month follow-up rhythm that makes this strategy work safely.

The STI burden in high-risk populations is real, the evidence is solid, and the tool is available. Know it, prescribe it appropriately, and talk about it without stigma.

 

 

References

•       Bachmann LH. CDC clinical guidelines on the use of doxycycline postexposure prophylaxis for bacterial sexually transmitted infection prevention, United States, 2024. MMWR Recomm Rep. 2024;73(2):1-8.

•       Molina JM et al. Post-exposure prophylaxis with doxycycline to prevent STIs in men who have sex with men (IPERGAY). Lancet Infect Dis. 2018;18(3):308-317.

•       Luetkemeyer AF et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections (US DoxyPEP Trial). N Engl J Med. 2023;388(14):1296-1306.

•       Stewart J et al. Doxycycline prophylaxis to prevent STIs in women (dPEP Kenya). N Engl J Med. 2023;389(25):2331-2340.

•       Molina JM et al. Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial STIs (DOXYVAC). Lancet Infect Dis. 2024;24(10):1093-1104.

•       Helekal D et al. Expansion of tetM-carrying Neisseria gonorrhoeae in the United States, 2018–2024. N Engl J Med. 2025;393(2):198-200.

•       Soge OO et al. Potential impact of doxyPEP on tetracycline resistance in N. gonorrhoeae and S. aureus. Clin Infect Dis. 2025;80(6):1188-1196.

•       Bacic Lima D. DoxyPEP in 2026: Who Benefits, How to Prescribe, and What to Watch. Infectious Disease Special Edition. April 23, 2026. idse.net

 

© 2026 NP Chronicles | Clinical Education for NP Students and New Graduates | npchronicles.com

This post is intended for educational purposes. Always consult current CDC guidelines, clinical guidelines, and your institutional protocols for patient care decisions.